NASDAQ: LFWDLifeward Ltd Stock
$8.00+0.05 (+0.63%)
Updated Jul 14, 2026
LFWD Price
$8.00
Fair Value Price
N/A
Market Cap
$22.52M
52 Week Low
$4.14
52 Week High
$10.20
P/E
-0.41x
P/B
3.58x
P/S
0.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.92M
Earnings
-$25.87M
Gross Margin
36.6%
Operating Margin
-120.25%
Profit Margin
-123.7%
Debt to Equity
4.31
Operating Cash Flow
-$15M
Beta
0.96
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LFWD Overview
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LFWD's potential to beat the market
- LFWD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LFWD
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.56 | A | |
| $44.34 | A | |
| $27.62 | A |
Be the first to know about important LFWD news, forecast changes, insider trades & much more!
LFWD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LFWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LFWD is poor value based on its book value relative to its share price (3.58x), compared to the US Medical Devices industry average (2.97x)
P/B vs Industry Valuation
LFWD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LFWD due diligence checks available for Premium users.
Valuation
LFWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
20.1x
Market
8.04x
LFWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.58x
Industry
2.97x
LFWD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LFWD's financial health
Profit margin
Revenue
$3.9M
Net Income
-$10.8M
Profit Margin
-275.1%
LFWD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LFWD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$33.4M
Liabilities
$27.1M
Debt to equity
4.31
LFWD's short-term assets ($25.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFWD's short-term assets ($25.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFWD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LFWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$6.5M
Financing
$6.4M
LFWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LFWD vs Medical Device Stocks
Lifeward Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.